CEO Of Dainippon Sumitomo Of Japan Justifies U.S.-Based Sepracor Buy
This article was originally published in PharmAsia News
Executive Summary
Japan's Dainippon Sumitomo Pharma may have made a risky deal in buying U.S. drug maker Sepracor, according to some, but CEO Masayo Tada said at a news conference the company has many financing options. Tada denied suggestions the $2.6 billion purchase price of Sepracor was excessive, saying Dainippon Sumitomo was financially healthy enough to manage the deal. The company was motivated to make the acquisition because of dwindling sales many drug makers are facing in Japan. (Click here for more - a subscription may be required